Immune checkpoint inhibitors and cardiovascular toxicity. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Lancet Oncol 19: e447-e458 Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Lancet Oncol 19: 1579-1589 High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC (2017) Sci Transl Med 9: Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE (2018) Heart 104: 1859-1863 Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J (2018) Br J Haematol 180: 271-275 Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM (2017) Curr Hematol Malig Rep 12: 257-267
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.